Molecular Partners Ag (MOLN) Receivables (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Receivables of $2953.7 for Q1 2026, down 33.23% year-on-year from $4423.4 in Q1 2025, and down 97.15% on a QoQ basis from $103639.4 in Q4 2025.
Molecular Partners Ag (MOLN) Receivables (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Receivables for 7 consecutive years, with $2953.7 the latest figure, recorded in Q1 2026.
- Quarterly Receivables fell 33.23% year-over-year to $2953.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2953.7 (down 33.23% YoY) and the FY2025 annual result came in at $2.4 million, down 12.32% from the prior year.
- Receivables retreated to $2953.7 in Q1 2026 per MOLN's latest filing, from $103639.4 in the prior quarter.
- Over the last five years, Receivables for MOLN reached as high as $20.7 million in Q2 2023 and fell as low as $1791.3 in Q3 2022.
- A 5-year average of $3.9 million and a median of $4354.4 in 2025 frame the typical range for Receivables.
- Annual changes were most pronounced in 2023 — Receivables soared 100.43% — and 2025, when it tumbled 99.98%.
- Year by year, Receivables stood at $1.1 million in 2022, then surged by 100.43% to $2.3 million in 2023, then increased by 20.06% to $2.7 million in 2024, then sank by 96.21% to $103639.4 in 2025, then tumbled by 97.15% to $2953.7 in 2026.
- According to Business Quant data, Receivables over the past three periods registered $2953.7, $103639.4, and $2629.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | 2,953.71 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,953.71 |
| Dec 31, 2025 | 103,639.40 |
| Sep 30, 2025 | 2,628.98 |
| Jun 30, 2025 | 4,354.44 |
| Mar 31, 2025 | 4,423.42 |
| Dec 31, 2024 | 2.73 Mn |
| Sep 30, 2024 | 3,829.66 |
| Jun 30, 2024 | 20.57 Mn |
| Mar 31, 2024 | 3,642.12 |
| Dec 31, 2023 | 2.28 Mn |
| Sep 30, 2023 | 2,022.02 |
| Jun 30, 2023 | 20.69 Mn |
| Mar 31, 2023 | 1,885.55 |
| Dec 31, 2022 | 1.14 Mn |
| Sep 30, 2022 | 1,791.34 |
| Jun 30, 2022 | 19.31 Mn |
| Mar 31, 2022 | 3,761.68 |
| Dec 31, 2021 | 27.98 Mn |
| Sep 30, 2021 | 6,079.52 |
| Dec 31, 2020 | 4.36 Mn |